Feeds › Planned insider sales
Planned insider sales
Notices (SEC Form 144) that executives and other insiders file before selling shares, and whether a sale was reported afterwards.
About this data
- What it is
- Before an executive, director or large owner sells restricted or control shares, they file a short notice with the SEC, called Form 144, saying how many shares they plan to sell, through which broker and roughly when. This feed lists those notices, and for each one shows whether a sale was reported afterwards on a Form 4 and how many days later.
- Who files it
- The person selling, or their broker, on the day the sale is placed. Electronic notices start in April 2023.
- How current
- We collect new notices throughout the day on SEC business days.
- Terms
- Form 144The notice an insider or other affiliate of a company files with the SEC before selling restricted or control shares, so the shares can be sold under Rule 144. The notice says how many shares, through which broker, and roughly when.10b5-1 planA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan.
- Worth knowing
- A notice is a plan, not a sale: the person may sell fewer shares, later, or not at all. The value is the one the filer typed, at a price they chose, not what the shares sell for. Many sales are routine, made to diversify or pay taxes, or under a 10b5-1 plan set up months earlier. A blank in the last column does not mean no sale: the person may not have to file a Form 4 (an ordinary affiliate does not), the sale may be recent, or the Form 4 may name a different spelling of the person. We match by the filer's number first and by name second. Information, not investment advice.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Form 144 notices per day, last 30 days
All notices Notices that give a 10b5-1 plan
By the day each notice was filed. A notice is a plan to sell, not a sale.
Latest notices of planned insider sales
Showing: ticker ARWR
| Filed | Insider | Company | Shares to sellA notice is a plan, not a sale. The person may sell fewer shares, sell later, or not sell at all, and the number of shares is what they expect to sell on the day they file. | ValueThe aggregate market value the filer typed on the notice: the shares times a price the filer chose. It is not what the shares will sell for. | PlanA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan. | Expected sale | Sale reportedInsiders who are officers, directors or hold more than 10% report their sales on a Form 4, within two business days. We look for the first Form 4 with an open-market sale by the same person in the same company within 90 days of the notice, and show how many days after the notice it was filed. A blank means we found none: the person may not have sold, may not have to file a Form 4, or the Form 4 may be one we do not have. | Notice |
|---|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | Adeoye Olukotun Director | ARWR Arrowhead Pharmaceuticals, Inc. | 2,000 | $173.9K | — | Aug 18, 2026 | Form 4 ↗ 2 days later · 2,000 shares | Form 144 ↗ |
| Aug 18, 2026 | Michael Perry Director | ARWR Arrowhead Pharmaceuticals, Inc. | 11,600 | $1.0M | — | Aug 18, 2026 | Form 4 ↗ 2 days later · 11,600 shares | Form 144 ↗ |
| May 19, 2026 amended | Daniel Apel Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 13,095 | $934.2K | 10b5-1 | Apr 22, 2026 | — | Form 144/A ↗ |
| May 19, 2026 amended | Hongbo Lu Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 2,970 | $228.3K | 10b5-1 | May 12, 2026 | — | Form 144/A ↗ |
| May 19, 2026 amended | James Hamilton Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 10,000 | $750.0K | 10b5-1 | Apr 23, 2026 | — | Form 144/A ↗ |
| May 12, 2026 | Hongbo Lu Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 2,970 | $228.3K | — | May 12, 2026 | Form 4 ↗ 2 days later · 2,970 shares | Form 144 ↗ |
| Apr 23, 2026 | James Hamilton Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 10,000 | $750.0K | — | Apr 23, 2026 | Form 4 ↗ 1 day later · 10,000 shares | Form 144 ↗ |
| Apr 22, 2026 | Daniel Apel Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 13,095 | $934.2K | — | Apr 22, 2026 | Form 4 ↗ 2 days later · 13,095 shares | Form 144 ↗ |
| Mar 5, 2026 | James Hamilton Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 10,000 | $641.9K | 10b5-1 | Mar 5, 2026 | Form 4 ↗ 4 days later · 10,000 shares | Form 144 ↗ |
| Jan 5, 2026 amended | James Hamilton Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 40,164 | $2.5M | 10b5-1 | Jan 5, 2026 | Form 4 ↗ same day · 40,164 shares | Form 144/A ↗ |
| Jan 5, 2026 | James Hamilton Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 39,728 | $2.5M | 10b5-1 | Jan 5, 2026 | Form 4 ↗ same day · 40,164 shares | Form 144 ↗ |
| Jan 5, 2026 | Patrick O'Brien Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 49,493 | $3.1M | 10b5-1 | Jan 5, 2026 | Form 4 ↗ same day · 49,493 shares | Form 144 ↗ |
| Jan 2, 2026 | Christopher Anzalone Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 13,187 | $871.7K | 10b5-1 | Jan 2, 2026 | Form 4 ↗ 3 days later · 13,187 shares | Form 144 ↗ |
| Dec 29, 2025 | Christopher Anzalone Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 51,726 | $3.6M | 10b5-1 | Dec 29, 2025 | Form 4 ↗ 1 day later · 51,726 shares | Form 144 ↗ |
| Dec 29, 2025 | Mauro Ferrari Director | ARWR Arrowhead Pharmaceuticals, Inc. | 7,530 | $527.1K | 10b5-1 | Dec 26, 2025 | Form 4 ↗ 1 day later · 7,530 shares | Form 144 ↗ |
| Dec 22, 2025 | Christopher Anzalone Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 12,586 | $861.3K | 10b5-1 | Dec 22, 2025 | Form 4 ↗ 1 day later · 26,031 shares | Form 144 ↗ |
| Dec 19, 2025 | Christopher Anzalone Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 13,445 | $909.6K | 10b5-1 | Dec 19, 2025 | Form 4 ↗ 4 days later · 26,031 shares | Form 144 ↗ |
| Dec 19, 2025 | William Waddill Director | ARWR Arrowhead Pharmaceuticals, Inc. | 8,367 | $566.0K | 10b5-1 | Dec 19, 2025 | Form 4 ↗ 4 days later · 8,367 shares | Form 144 ↗ |
| Dec 19, 2025 | Adeoye Olukotun Director | ARWR Arrowhead Pharmaceuticals, Inc. | 10,000 | $676.6K | 10b5-1 | Dec 19, 2025 | Form 4 ↗ 4 days later · 10,000 shares | Form 144 ↗ |
| Dec 19, 2025 | Victoria Vakiener Director | ARWR Arrowhead Pharmaceuticals, Inc. | 10,040 | $679.5K | 10b5-1 | Dec 19, 2025 | Form 4 ↗ 4 days later · 10,040 shares | Form 144 ↗ |
| Dec 17, 2025 | Christopher Anzalone Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 85,000 | $5.4M | — | Dec 17, 2025 | Form 4 ↗ 2 days later · 85,000 shares | Form 144 ↗ |
| Dec 16, 2025 | Christopher Anzalone Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 54,298 | $3.4M | — | Dec 16, 2025 | Form 4 ↗ same day · 184,298 shares | Form 144 ↗ |
| Dec 15, 2025 | Christopher Anzalone Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 130,000 | $9.0M | — | Dec 15, 2025 | Form 4 ↗ 1 day later · 184,298 shares | Form 144 ↗ |
| Dec 5, 2025 | Michael Perry Director | ARWR Arrowhead Pharmaceuticals, Inc. | 16,250 | $991.1K | — | Dec 5, 2025 | Form 4 ↗ 4 days later · 16,250 shares | Form 144 ↗ |
| Nov 28, 2025 | Mauro Ferrari Director | ARWR Arrowhead Pharmaceuticals, Inc. | 8,750 | $493.1K | — | Nov 28, 2025 | Form 4 ↗ 3 days later · 8,750 shares | Form 144 ↗ |
| Oct 1, 2025 | James Hamilton Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 20,000 | $700.0K | 10b5-1 | Oct 1, 2025 | Form 4 ↗ 2 days later · 20,000 shares | Form 144 ↗ |
| Sep 12, 2025 | James C. Hamilton Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 15,000 | $450.0K | 10b5-1 | Sep 12, 2025 | Form 4 ↗ 4 days later · 15,000 shares | Form 144 ↗ |
| Sep 2, 2025 | James C. Hamilton Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 15,000 | $375.0K | 10b5-1 | Sep 2, 2025 | Form 4 ↗ 2 days later · 15,000 shares | Form 144 ↗ |
| Aug 15, 2025 | James C. Hamilton Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 9,389 | $187.8K | 10b5-1 | Aug 15, 2025 | Form 4 ↗ same day · 10,000 shares | Form 144 ↗ |
| Aug 13, 2025 | James C. Hamilton Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 611 | $12.2K | 10b5-1 | Aug 13, 2025 | Form 4 ↗ 2 days later · 10,000 shares | Form 144 ↗ |
| Aug 13, 2025 | Sarepta Therapeutics, Inc. Shareholder | ARWR Arrowhead Pharmaceuticals, Inc. | 9.27M | $185.2M | — | Aug 13, 2025 | — | Form 144 ↗ |
| Jul 10, 2025 | Myszkowski Kenneth Allen Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 40,000 | $761.7K | — | Jul 10, 2025 | — | Form 144 ↗ |
| Apr 11, 2025 | Christopher Richard Anzalone Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 50,800 | $583.8K | — | Apr 11, 2025 | Form 4 ↗ same day · 141,122 shares | Form 144 ↗ |
| Apr 10, 2025 | Christopher Richard Anzalone Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 50,000 | $543.2K | — | Apr 10, 2025 | Form 4 ↗ 1 day later · 141,122 shares | Form 144 ↗ |
| Apr 9, 2025 | Christopher Richard Anzalone Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 40,322 | $406.1K | — | Apr 9, 2025 | Form 4 ↗ 2 days later · 141,122 shares | Form 144 ↗ |
| Mar 13, 2025 | Christopher Richard Anzalone Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 51,425 | $774.8K | — | Mar 13, 2025 | Form 4 ↗ 4 days later · 51,425 shares | Form 144 ↗ |
| Mar 4, 2025 | Christopher Richard Anzalone Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 133,333 | $2.3M | 10b5-1 | Mar 4, 2025 | Form 4 ↗ 1 day later · 300,000 shares | Form 144 ↗ |
| Mar 3, 2025 | Christopher Richard Anzalone Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 166,667 | $3.0M | 10b5-1 | Mar 3, 2025 | Form 4 ↗ 2 days later · 300,000 shares | Form 144 ↗ |
| Jan 23, 2025 | Adeoye Y. Olukotun Director | ARWR Arrowhead Pharmaceuticals, Inc. | 959 | $20.1K | 10b5-1 | Jan 23, 2025 | Form 4 ↗ 4 days later · 959 shares | Form 144 ↗ |
| Jan 7, 2025 | Myszkowski Kenneth Allen Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 10,000 | $196.9K | — | Jan 7, 2025 | Form 4 ↗ same day · 45,167 shares | Form 144 ↗ |
| Jan 7, 2025 | Myszkowski Kenneth Allen Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 8,000 | $157.5K | 10b5-1 | Jan 7, 2025 | Form 4 ↗ same day · 45,167 shares | Form 144 ↗ |
| Jan 7, 2025 | Patrick O'Brien Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 8,000 | $157.5K | 10b5-1 | Jan 7, 2025 | Form 4 ↗ same day · 37,184 shares | Form 144 ↗ |
| Jan 6, 2025 | Myszkowski Kenneth Allen Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 5,817 | $115.3K | 10b5-1 | Jan 6, 2025 | Form 4 ↗ 1 day later · 45,167 shares | Form 144 ↗ |
| Jan 6, 2025 | Myszkowski Kenneth Allen Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 9,255 | $183.5K | 10b5-1 | Jan 6, 2025 | Form 4 ↗ 1 day later · 45,167 shares | Form 144 ↗ |
| Jan 6, 2025 | Myszkowski Kenneth Allen Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 6,287 | $124.5K | 10b5-1 | Jan 6, 2025 | Form 4 ↗ 1 day later · 45,167 shares | Form 144 ↗ |
| Jan 6, 2025 | Myszkowski Kenneth Allen Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 5,817 | $115.3K | 10b5-1 | Jan 6, 2025 | Form 4 ↗ 1 day later · 45,167 shares | Form 144 ↗ |
| Jan 6, 2025 | James C. Hamilton Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 32,729 | $648.7K | 10b5-1 | Jan 6, 2025 | Form 4 ↗ 1 day later · 32,729 shares | Form 144 ↗ |
| Jan 6, 2025 | Patrick O'Brien Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 29,184 | $578.5K | 10b5-1 | Jan 6, 2025 | Form 4 ↗ 1 day later · 37,184 shares | Form 144 ↗ |
| Jan 2, 2025 | Christopher Richard Anzalone Officer | ARWR Arrowhead Pharmaceuticals, Inc. | 11,520 | $219.4K | 10b5-1 | Jan 2, 2025 | Form 4 ↗ 4 days later · 11,520 shares | Form 144 ↗ |
| Dec 27, 2024 | Adeoye Y. Olukotun Director | ARWR Arrowhead Pharmaceuticals, Inc. | 2,850 | $57.0K | 10b5-1 | Dec 27, 2024 | Form 4 ↗ 3 days later · 2,850 shares | Form 144 ↗ |
The newest 50 items, most recent first. Every row links to the notice on the SEC's site, and to the Form 4 when we found one. Updated Nov 15, 2026, 9:35 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances